Improving the Biophysical Activity of Dysfunctional Lung Surfactant Vanessa Sousa Ventura College Chemistry Lab Mentor: Ian Shieh Faculty Advisor: Dr. Joseph Zasadzinski Chemical Engineering Department, UCSB
Lung Surfactant & ARDS • What is Lung Surfactant? – Lowers Surface Tension in Lungs Air • Acute Respiratory Distress Syndrome (ARDS) Surfactant – Surfactant Deactivation – In the U.S., 150,000 cases/year, 40% mortality rate Liquid • Reversal of Surfactant Deactivation Notter, R.H., ed. Lung Surfactants: Basic Science and Clinical Applications. 1 ed. Lung Biology in Health and Disease, ed. C. Lenfant. Vol. 149. 2000, Marcel Dekker, Inc.: New York, N.Y. 444. http://www.lawsonresearch.com/v1.0/website/lung/images/lungs_1.jpg http://services.epnet.com/GetImage.aspx/getImage.aspx?ImageIID=2547 http://www.scitech.ac.uk/PandS/Gallery/ISISbeauty/ISISlbf0004.jpg
Albumin & Competitive Adsorption • Lung Surfactant Meets Albumin – Main Protein in Blood Serum Interface Albumin Albumin Albumin • Competitive Adsorption – Albumin Blocks Lung Surfactant from Interface Surfactant Subphase (Liquid) Aggregates
Langmuir Trough • Our Model of the Human Lung Thermometer – Expansion & Compression of Barriers Surface Pressure Sensor Metal Barriers
Modeling Lung Behavior • The Healthy Lung Metal Barriers – Survanta (Lung Surfactant) – Rapid Adsorption • ARDS – Albumin – Surfactant Inhibition • Reversing ARDS with Polyethylene glycol (PEG) – Hydrophilic Polymer – Shown to enable re ‐ adsorption Saline Solution
Confocal Microscopy • Simultaneous Multiple Imaging – Fluorescently View & Track Three Molecules at the Same Time Lung Surfactant Albumin PEG • Optical Sectioning Capability Air – Image Slices Taken at Z (µm) Interface Various Depths Subphase (Liquid)
Surface Pressure vs. Area • Unique Shapes – Tells Type of Molecule at Surface Pressure (mN/m) Surface Pressure (mN/m) Surface Pressure (mN/m) 70 70 70 Albumin Only Albumin Only Interface Albumin & Survanta Albumin & Survanta 60 60 60 Albumin,Survanta,& PEG Albumin Only • Surface Pressure 50 50 50 in Saline Soln. – High Surface Pressure = 40 40 40 Low Surface Tension – Can Evaluate Effectiveness 30 30 30 of Surfactant at Interface 20 20 20 • Our Models 10 10 10 – The Healthy Lung 0 0 0 – Albumin 30 40 50 60 70 80 90 100 30 40 50 60 70 80 90 100 30 40 50 60 70 80 90 100 – Lung Surfactant Inhibition Trough Area (%) Trough Area (%) Trough Area (%) – PEG Reversal of Inhibition
Intensity Profiles Normalized Fluorescence Intensity Normalized Fluorescence Intensity • Fluorescence Intensity Survanta 1.0 1.0 – Peak Occurs at Interface Only Albumin 0.8 0.8 – Indicates Molecule Only Location (in terms of 0.6 0.6 depth) 0.4 0.4 • Our Models 0.2 0.2 – The Healthy Lung 0.0 0.0 – Albumin -5 -5 0 0 5 5 10 10 15 15 Depth ( µ m ) Depth ( µ m ) Air Subphase
Confocal Images 50 µm 20 µm 100 µm Survanta Only Albumin Only Survanta/Albumin with PEG Albumin,Survanta,& PEG Albumin Only in Saline Soln.
Project Overview & Future Goals • What I Learned This Summer – Importance of Lung Surfactant – ARDS/Inhibition Process – Langmuir Trough/Microscopy Techniques • Continuing Research – Reversal Process Was Unsuccessful • New Sample of Survanta – Use Three Lasers • We Have Only Used Two
Thank You to: Ian Shieh, Mentor Dr. Joseph Zasadzinski, Faculty Advisor Dr. Jens ‐ Uwe Kuhn, Program Coordinator “Dr. Nick” Arnold, Faculty Coordinator For Funding Our Project
Polyethylene glycol (PEG) • PEG Mechanism – Excluded Volumes Surround Surfactant Aggregates – PEG Helps Aggregates Stick Together & to the Interface – Rise In Entropy Excluded Volumes of System Excluded Volumes Overlap Frees Volume Ian Shieh, Zasadzinski Lab
Lung Cancer : Lung Cancer : Lung Cancer : Lung Cancer : Improving the Cure
8/19/2018 LUNG CANCER SCREENING IMPROVING LUNG CANCER SURVIVAL IN THE
Improving the implementation of lung cancer screening guidelines at UNC
Getting the Functional out of Getting the Functional out of Dysfunctional
Moms Company Rule Dysfunctional Momentum and Master Clinicians Gerard M.
ADDRESSING LUNG CANCER STIGMA Katherine Pruitt National Assistant Vice
ALICE : Improving biophysical models to link terrestrial, riverine and
NCUK Marketing Activity MEET THE TEAM 4 KEY INITIATIVES IN 2018 Improving
Improving Therapy for EGFR-Mutant Lung Cancers Zosia Piotrowska, MD
Lung Cancer in Kentucky: Improving Patient Outcomes Kentucky LEADS
Intercept 1Q16 Earnings Presentation May 5 th , 2016 Safe Harbor Statement
Oxford Inflammatory Bowel Disease MasterClass Medical management of high
Workshop Argentina-Japan Bioscience and Biotechnology for the Promotion of
Pot otentia ial l trial d des esigns s and suitable e study populati
A detailed look at impurities in medicines Dr John Churchill Principal
Pediatric Anesthesia and Critical Care Journal 2013; 1(2):98-101
A 12 Year Old with Liver Disease and Pulmonary Hypertension Russel Hirsch,
[Downloaded free from http://www.amhsr.org] Case Report Systemic Lupus
Make it count Technical considerations and initial findings for accurate
SUBMIT Cas ase P e Presen entat ation COVID-19 Kurt DeVine, MD and
Glycocalyx Loss Podocyte and Kidney Injury Induces Albuminuria Nat Rev
Management of Management of Hypertension Hypertension M Misra MD MRCP (UK)